Talphera (TLPH) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 18.2% versus a loss of 62.7%. Talphera is the larger company by market cap ($56.1 million vs $55.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLPH | ZYBT |
|---|---|---|
| Share price | $1.08 | $1.16 |
| Market cap | $56.06M | $54.97M |
| 1-day change | 0.00% | +0.88% |
| YTD return | -5.26% | -0.01% |
| 1-year return | -18.18% | -62.67% |
| 5-year return | -94.71% | — |
| EPS (TTM) | $-0.26 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.57 | $8.01 |
| 52-week low | $0.69 | $0.616 |
| Distance from 52-week high | -31.21% | -85.52% |
| Analyst consensus | none | — |
| Avg. price target upside | +189.81% | — |
| Average volume | 238.38K | 5.10M |
| Shares outstanding | 51.91M | 47.39M |
| Employees | 12 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed ZYBT by 44.5 percentage points over the past year.
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
TLPH vs ZYBT FAQ
Which is bigger, Talphera or Zhengye Biotechnology?
Talphera (TLPH) is larger, with a market capitalization of $56.06M compared with $54.97M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, TLPH or ZYBT?
TLPH returned -18.18% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Talphera and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.